Expression of ICAM-1, HLA-DR, and CD80 on peripheral circulating CD1 alpha DCs induced in vivo by IFN-alpha in patients with chronic hepatitis B.
OBJECTIVE
To explore the effects of interferon-alpha (IFN-alpha) application on peripheral circulating CD1alpha dendritic cells (DCs)in patients with chronic hepatitis B, and the expression of HLA-DR, CD80, and ICAM-1 on CD1alpha DCs in order to explore the mechanism of immune modulation of IFN-alpha.


METHODS
By flow cytometry technique, changes of CD1alpha DCs were monitored in 22 patients with chronic hepatitis B treated with IFN-alpha and in 16 such patients not treated with IFN-alpha within three months. Meanwhile, the expression of HLA-DR, CD80, and ICAM-1 on CD1alpha DCs was detected.


RESULTS
In the group of IFN-alpha treatment, the percentage of CD1alpha DCs in peripheral blood mononuclear cells was increased after three months of therapy. In patients who became negative for HBV-DNA after IFN-alpha treatment, the increase of DCs was more prominent, while in control, these changes were not observed. Increased expression of HLA-DR, CD80,and ICAM-1 on CD1alpha DCs was also observed.


CONCLUSIONS
CD1alpha DCs can be induced by IFN-alpha in vivo, and the immune related molecules such as HLA-DR, CD80,and ICAM-1 are up-regulated to some degree. This might be an important immune related mechanism of IFN-alpha treatment for chronic hepatitis B.
Yu
Yong-Sheng
YS
Department of Infectious Diseases, Sixth People's Hospital of Shanghai Jiaotong University, Shanghai 200233,China. yuyongsheng@medmail.com.cn
Tang
Zheng-Hao
ZH
Han
Jing-Chao
JC
Xi
Min
M
Feng
Jie
J
Zang
Guo-Qing
GQ
D000328:Adult; D018949:Antigens, CD1 / Q000032:analysis*; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018122:B7-1 Antigen / Q000032:analysis*; D004279:DNA, Viral / Q000032:analysis; D003713:Dendritic Cells / Q000737:chemistry / Q000187:drug effects* / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D005434:Flow Cytometry; D006684:HLA-DR Antigens / Q000032:analysis*; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis*; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D018949:Antigens, CD1; D000998:Antiviral Agents; D018122:B7-1 Antigen; D004279:DNA, Viral; D006684:HLA-DR Antigens; D016898:Interferon-alpha; D018799:Intercellular Adhesion Molecule-1